These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7695323)

  • 21. Gastric emptying and the pharmacokinetics of the cephalosporin antibiotic, cefpodoxime proxetil.
    Hughes GS; Heald DL; Patel R; Spillers CR; Batts DH; Euler AR
    Methods Find Exp Clin Pharmacol; 1990 Apr; 12(3):197-204. PubMed ID: 2352449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.
    Borin MT; Hughes GS; Spillers CR; Patel RK
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1094-9. PubMed ID: 2393268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disposition of cefpodoxime proxetil in hemodialysis patients.
    Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
    J Clin Pharmacol; 1992 Nov; 32(11):1038-44. PubMed ID: 1474165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trials of cefpodoxime proxetil suspension in paediatrics.
    Fujii R
    Drugs; 1991; 42 Suppl 3():57-60. PubMed ID: 1726209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers.
    O'Neill P; Nye K; Douce G; Andrews J; Wise R
    Antimicrob Agents Chemother; 1990 Feb; 34(2):232-4. PubMed ID: 2327771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, protein binding, and tissue distribution of orally administered cefpodoxime proxetil and cephalexin in dogs.
    Papich MG; Davis JL; Floerchinger AM
    Am J Vet Res; 2010 Dec; 71(12):1484-91. PubMed ID: 21118001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients.
    Muller-Serieys C; Bancal C; Dombret MC; Soler P; Murciano G; Aubier M; Bergogne-Berezin E
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2099-103. PubMed ID: 1444291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis.
    Höffler D; Koeppe P; Corcilius M; Przyklinik A
    Infection; 1990; 18(3):157-62. PubMed ID: 2365467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
    Fulton B; Perry CM
    Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition of orally administered cefpodoxime proxetil in foals and adult horses and minimum inhibitory concentration of the drug against common bacterial pathogens of horses.
    Carrillo NA; Giguère S; Gronwall RR; Brown MP; Merritt KA; O'Kelley JJ
    Am J Vet Res; 2005 Jan; 66(1):30-5. PubMed ID: 15691032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue.
    Naber KG; Kinzig M; Adam D; Sörgel F; Bajorski AH; Kiehn R
    Infection; 1991; 19(1):30-5. PubMed ID: 1707399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo.
    Chachaty E; Depitre C; Mario N; Bourneix C; Saulnier P; Corthier G; Andremont A
    Antimicrob Agents Chemother; 1992 Sep; 36(9):2009-13. PubMed ID: 1416894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections.
    Stevens DL; Pien F; Drehobl M
    Diagn Microbiol Infect Dis; 1993 Feb; 16(2):123-9. PubMed ID: 8467623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of cefpodoxime proxetil oral absorption in rats by an oil-in-water submicron emulsion.
    Nicolaos G; Crauste-Manciet S; Farinotti R; Brossard D
    Int J Pharm; 2003 Sep; 263(1-2):165-71. PubMed ID: 12954191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple dose pharmacokinetics of cefpodoxime in young adult and elderly patients.
    Backhouse C; Wade A; Williamson P; Tremblay D; Lenfant B
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():29-34. PubMed ID: 2292527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid pharmacokinetics of cefpodoxime proxetil in piglets.
    Abdel-Rahman SM; Maxson S; Teo C; Hubbard AE; Kearns GL
    J Clin Pharmacol; 2000 Mar; 40(3):290-5. PubMed ID: 10709158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
    Balfour JA; Benfield P
    Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of nifedipine and diltiazem on pharmacokinetics of cefpodoxime following its oral administration.
    Deslandes A; Camus F; Lacroix C; Carbon C; Farinotti R
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2879-81. PubMed ID: 9124858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies.
    Baldwin DR; Wise R; Andrews JM; Honeybourne D
    J Antimicrob Chemother; 1992 Jul; 30(1):67-71. PubMed ID: 1429338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly sensitive and selective high-performance liquid chromatography method for bioequivalence study of cefpodoxime proxetil in rabbit plasma via fluorescence labeling of its active metabolite.
    Ahmed S; Abdel-Wadood HM; Mohamed NA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Sep; 934():34-40. PubMed ID: 23896427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.